Dr. Burgess on Pembrolizumab in SarcomaByMelissa Burgess, MDJanuary 17th 2017In the phase II SARC028 trial, single-agent pembrolizumab (Keytruda) demonstrated antitumor activity in patients with advanced soft tissue and bone sarcomas.